Silveira Patrick, Razmaria Aria, Yeh Randy
From the Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.
Clin Nucl Med. 2024 Jul 1;49(7):e373-e374. doi: 10.1097/RLU.0000000000005257. Epub 2024 May 2.
A 62-year-old man with de novo large volume metastatic prostate cancer to the bone, liver, and nodes status post multiple lines of therapy including external beam radiation to T12-L2 approximately 13 months prior underwent 68 Ga-PSMA PET/CT to determine eligibility for 177 Lu-PSMA therapy. 68 Ga-PSMA PET/CT demonstrated tracer-avid osseous and nodal lesions consistent with metastases. In addition, regional geographic tracer avidity was seen in the midline left hepatic lobe associated with capsular retraction and demonstrated no FDG avidity on subsequent imaging, probably inflammatory related to prior radiation to T12-L2.
一名62岁男性,患有新发大量骨、肝和淋巴结转移的前列腺癌,此前接受了包括约13个月前对T12-L2进行外照射放疗在内的多线治疗,现接受68 Ga-PSMA PET/CT检查以确定是否适合177 Lu-PSMA治疗。68 Ga-PSMA PET/CT显示与转移灶一致的放射性摄取骨和淋巴结病变。此外,在左肝中叶中线区域可见区域性放射性摄取,伴有包膜回缩,后续影像显示无FDG摄取,可能与先前T12-L2放疗相关的炎症有关。